Erschienen in:
31.07.2020 | ASO Author Reflections
ASO Author Reflections: Omission of Axillary Lymph Node Dissection for Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy: Not Ready for Primetime?
verfasst von:
Muayad F. Almahariq, MD, PhD, Peter Y. Chen, MD, Nayana Dekhne, MD, Joshua T. Dilworth, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2020
Einloggen, um Zugang zu erhalten
Excerpt
Axillary lymph node dissection (ALND) serves to stage the axilla and provide regional control in breast cancer patients but adversely impacts quality of life.
1 There have been increasing efforts over the last 2 decades to omit ALND in favor of the less morbid sentinel lymph node dissection (SLND). Two seminal trials, ACOSOG Z0011 and AMAROS, clearly established the feasibility of SLND alone in patients with limited nodal metastasis who do not receive neoadjuvant chemotherapy (NAC).
2,
3 However, it is unclear whether omission of ALND compromises clinical outcomes in patients with residual nodal disease following NAC. This question is the subject of the ongoing ALLIANCE A011202 trial. …